Vasopressin-induced cytoplasmic and nuclear calcium signaling in cultured cortical astrocytes.
We sought to determine whether vasopressin V(1a) receptor (V(1a)R) mRNA detected in cortical astrocytes [Brain Res. Mol. Brain Res. 45 (1997) 138] was translated into functional receptors by investigating the effector calcium signaling cascade associated with the vasopressin V(1a) receptor subtype. Analysis of intracellular calcium dynamics using the calcium-sensitive dye fura-2 AM indicated that exposure of cortical astrocytes to V(1) vasopressin receptor agonist, [Phe(2),Orn(8)]-oxytocin, induced a marked dose-dependent increase in intracellular calcium which was abolished by depletion of extracellular calcium. V(1) agonist treatment induced a rapid increase in calcium signal in both the cytoplasm and nucleus, which was followed by an accumulation of the calcium signal in the nucleus, suggesting translocation of cytoplasmic calcium into the nucleus. The nuclear calcium signal was sustained for several seconds followed by translocation back to the cytoplasm. Following the nuclear-to-cytoplasmic calcium translocation, total free intracellular calcium concentration decreased. The dynamic calcium cytoplasmic and nuclear localization was confirmed by laser scanning confocal microscopy coupled with the calcium-sensitive dye fluo-3 AM. To determine the source of calcium, V(1) agonist-induced (45)Ca(2+) uptake and [(3)H]IP(1) accumulation were investigated. V(1) agonist induced significant and rapid uptake of (45)Ca(2+) and a significant dose-dependent increase in [(3)H]IP(1) accumulation in cortical astrocytes. To our knowledge, this is the first documentation of a vasopressin receptor-induced calcium signaling cascade in cortical astrocytes and the first documentation of vasopressin receptor induction of nuclear calcium signaling.
Zhao
Lixia
L
Department of Molecular Pharmacology and Toxicology, University of Southern California, Pharmaceutical Sciences Center, Los Angeles, CA 90089, USA.
Brinton
Roberta Diaz
RD
D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D001253:Astrocytes / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D002118:Calcium / Q000378:metabolism; D020013:Calcium Signaling / Q000187:drug effects / Q000502:physiology*; D002467:Cell Nucleus / Q000378:metabolism*; D002478:Cells, Cultured; D002540:Cerebral Cortex / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D003593:Cytoplasm / Q000187:drug effects / Q000378:metabolism*; D005333:Fetus; D007424:Intracellular Fluid / Q000187:drug effects / Q000378:metabolism; D010121:Oxytocin / Q000031:analogs & derivatives* / Q000494:pharmacology; D051381:Rats; D017483:Receptors, Vasopressin / Q000819:agonists / Q000096:biosynthesis*; D014667:Vasopressins / Q000494:pharmacology*
D065092:Antidiuretic Hormone Receptor Antagonists; D017483:Receptors, Vasopressin; D014667:Vasopressins; C047063:oxytocin, Phe(2)-Orn(8)-; D010121:Oxytocin; D002118:Calcium